Form 4: Intra-Cellular Therapies Director Van Nostrand Reports Share Disposal Following Johnson & Johnson Merger
SEC Form 4
Director Robert L. Van Nostrand reports the disposal of Intra-Cellular Therapies shares and derivative securities following the completion of the merger with Johnson & Johnson on April 2, 2025.
Summary
- Robert L. Van Nostrand, a director of Intra-Cellular Therapies, Inc., filed a Form 4 on April 2, 2025, reporting changes in beneficial ownership.
- The filing details the disposal of common stock and derivative securities (stock options and restricted stock units) due to the merger between Intra-Cellular Therapies and Johnson & Johnson, which became effective on April 2, 2025.
- The merger consideration was $132.00 per share in cash.
- Outstanding stock options with an exercise price less than $132.00 were canceled and converted into the right to receive a cash payment equal to the difference between $132.00 and the exercise price, multiplied by the number of shares underlying the option.
- Options with an exercise price equal to or exceeding $132.00 were canceled for no consideration.
- Restricted stock units (RSUs) were canceled and converted into the right to receive $132.00 per share, with RSUs granted in 2025 payable at the original vesting date, subject to accelerated vesting in certain circumstances.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The document describes a completed merger, which is generally a positive event for shareholders who receive a cash payout. The director's actions are simply a consequence of the merger agreement.
Future Outlook
The company will continue as a wholly owned subsidiary of Parent, effective as of April 2, 2025.
Industry Context
This announcement reflects a significant consolidation in the pharmaceutical industry, with Johnson & Johnson acquiring Intra-Cellular Therapies. Such acquisitions are common in the sector as larger companies seek to expand their pipelines and market presence.
Comparison to Industry Standards
- Merger and acquisition activity is a common strategy in the pharmaceutical industry.
- Johnson & Johnson's acquisition of Intra-Cellular Therapies is similar to other large pharmaceutical companies acquiring smaller biotech firms with promising drug candidates.
- The $132 per share acquisition price is within the typical range for acquisitions of biotech companies with approved drugs and strong pipelines.
Stakeholder Impact
- Shareholders received $132.00 per share in cash.
- Employees of Intra-Cellular Therapies now work for a subsidiary of Johnson & Johnson.
- The merger may impact the company's relationships with suppliers and customers.
Key Dates
| Date | Description |
|---|---|
| January 10, 2025 | Date of the Agreement and Plan of Merger between Intra-Cellular Therapies, Johnson & Johnson, and Fleming Merger Sub, Inc. |
| April 2, 2025 | Effective date of the merger between Intra-Cellular Therapies and Johnson & Johnson. |
| April 2, 2025 | Date of the Form 4 filing by Robert L. Van Nostrand. |
| June 15, 2025 | Expiration date of some stock options. |
| June 13, 2026 | Expiration date of some stock options. |
| June 17, 2028 | Expiration date of some stock options. |
| May 26, 2030 | Expiration date of some stock options. |
| June 20, 2031 | Expiration date of some stock options. |
| June 8, 2032 | Expiration date of some stock options. |
| June 22, 2033 | Expiration date of some stock options. |
| June 13, 2034 | Expiration date of some stock options. |
Keywords
Form 4, Intra-Cellular Therapies, Johnson & Johnson, Merger, Beneficial Ownership, Director, Stock Options, Restricted Stock Units, ITCI
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.